Institutional investors purchased a net $1.8 million shares of MACK during the quarter ended December 2012, and now own 43.74% of the total float, a percentage that is typical for companies in the Biotechnology industry.
| Individual stakeholders | 6.70% |
| Mutual fund holders | 26.21% |
| Other institutional | 17.52% |